BP Limb Length as a Factor for T2DM Remission

Main Article Content

José Antonio Alvarez-Ortiz
Carlos Rene Lopez-Lizarraga
Carlos Manuel Moreno-Mendoza
Ma Soledad Aldana-Aguiñaga
Víctor Manuel Navarro-Navarro
Luis Manuel Flores Chavez
Fabian Patricio Jimenez-Zeas
Mariana del Rocío Ruiz-Briseño
Allison Rukmini Esparza-Yañez
Martha Patricia Sánchez-Muñoz
César Alberto Ortiz Orozco

Abstract

Background: There has been increased interest in identifying the associated factors to Type 2 Diabetes Mellitus (T2DM) remission after bariatric surgery. One of these factors is the BP limb length. The objective of our study was to evaluate the T2DM remission rate in patients subjected to Roux -en- Y gastric bypass (RYGB) who had different Biliopancreatic (BP) limbs length.


Methods: 48 patients with obesity grade II, and T2DM diagnosis, were subjected to RYGB and completed a one year of surgical follow up. All patients were grouped according to the BP limb length: In group A (n= 24) patients with BP limbs of 100 cm or less; in group B (n= 24) patients with BP limb from 150 to 170 cm in length.


Results: Both groups presented an elevated remission rate of T2DM (83% full remission in the population studied). In group A 18 patients (75%) presented a full remission, while 2 patients (8.3%) showed a partial remission and only 4 patients (16.7%) were considered without remission at the one year follow up. In group B all patients had some remission: 22 patients (91.7%) presented a full remission (91.7%) and the rest of the patients showed a partial remission (8.3%), no significant difference was found between the two groups.  


Conclusions: Bariatric surgery remains as the best long term treatment for obesity and its comorbidities, despite some differences in the RYGB technique, BP limb length from 50 to 170 cm did not affect post RYGB glycemic control.

Article Details

How to Cite
José Antonio Alvarez-Ortiz, Carlos Rene Lopez-Lizarraga, Carlos Manuel Moreno-Mendoza, Ma Soledad Aldana-Aguiñaga, Víctor Manuel Navarro-Navarro, Luis Manuel Flores Chavez, Fabian Patricio Jimenez-Zeas, Mariana del Rocío Ruiz-Briseño, Allison Rukmini Esparza-Yañez, Martha Patricia Sánchez-Muñoz, & César Alberto Ortiz Orozco. (2023). BP Limb Length as a Factor for T2DM Remission. International Journal of Medical Science and Clinical Research Studies, 3(3), 394–399. https://doi.org/10.47191/ijmscrs/v3-i3-21
Section
Articles

References

I. Blüher M. Obesity: global epidemiology and pathogenesis. Nature Reviews Endocrinology. 2019;15(5):288–98.

II. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circulation Research. 2016;118(11):1723–35.

III. Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L. The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis. Obesity Surgery. 2017;27(10):2724–32.

IV. Jans A, Näslund I, Ottosson J, Szabo E, Näslund E, Stenberg E. Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007-2015: A registry-based cohort study. PLoS Medicine. 2019;16(11):1–13.

V. Peterli R, Wolnerhanssen BK, Peters T, Vetter D, Kroll D, Borbely Y, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass onweight loss in patients with morbid obesity the sm-boss randomized clinical trial. Journal of the American Medical Association. 2018;319(3):255–65.

VI. Palermo M, Serra E. SIMPLIFIED LAPAROSCOPIC GASTRIC BYPASS WITH GASTROJEJUNAL LINEAR MECHANICAL ANASTOMOSIS : ABCD Arq Bras Cir Dig. 2016;29:91–4.

VII. Salinari S, Carr RD, Guidone C, Bertuzzi A, Cercone S, Riccioni ME, et al. Nutrient infusion bypassing duodenum-jejunum improves insulin sensitivity in glucose-tolerant and diabetic obese subjects. American Journal of Physiology - Endocrinology and Metabolism. 2013;305(1).

VIII. Ke Z, Li F, Gao Y, Zhou X, Sun F, Wang L, et al. Short versus long biliopancreatic limb in Roux-en-Y gastric bypass surgery for treatment of type 2 diabetes mellitus. Videosurgery and Other Miniinvasive Techniques. 2021;16(1):129–38.

IX. Madadi F, Jawad R, Mousati I, Plaeke P, Hubens G. Remission of Type 2 Diabetes and Sleeve Gastrectomy in Morbid Obesity: a Comparative Systematic Review and Meta-analysis. Obesity Surgery. 2019;29(12):4066–76.

X. Mahawar KK, Kumar P, Parmar C, Graham Y, Carr WRJ, Jennings N, et al. Small Bowel Limb Lengths and Roux-en-Y Gastric Bypass: a Systematic Review. Obesity Surgery. 2016;26(3):660–71.

XI. Homan J, Boerboom A, Aarts E, Doga K, Laarhoven C van, Janssen I, et al. A longer biliopancreatic limb in Roux-en-Y gastric bypass results in more weight loss and remission of type 2 diabetes mellitus: A randomized controlled trial. Obesity Surgery [Internet]. 2015;25(1 SUPPL. 1):S49. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=72002726

XII. Moon RC, Bornstein A, Teixeira AF, Jawad MA. Short-term results of long biliopancreatic limb Roux-en-Y gastric bypass—is it superior? Surgery for Obesity and Related Diseases [Internet]. 2020;16(4):492–6. Available from: https://doi.org/10.1016/j.soard.2019.12.021

XIII. Nora M, Morais T, Almeida R, Guimarães M, Monteiro MP. Should Roux-en-Y gastric bypass biliopancreatic limb length be tailored to achieve improved diabetes outcomes? Medicine (United States). 2017;96(48).

XIV. Ruiz-Tovar J, Vorwald P, Gonzalez-Ramirez G, Posada M, Salcedo G, Llavero C, et al. Impact of Biliopancreatic Limb Length (70 cm vs 120 cm), with Constant 150 cm Alimentary Limb, on Long-Term Weight Loss, Remission of Comorbidities and Supplementation Needs After Roux-En-Y Gastric Bypass: a Prospective Randomized Clinical Trial. Obesity Surgery. 2019;29(8):2367–72.

Most read articles by the same author(s)